Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;59(2):968-982.
doi: 10.1007/s12035-021-02638-w. Epub 2021 Nov 23.

CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders

Lihong Guan  1   2   3   4 , Yawei Han  5 , Ciqing Yang  1   2   3 , Suxiang Lu  6 , Jiang Du  2   3   7 , Han Li  1   2   3 , Juntang Lin  8   9   10   11
Affiliations
Review

CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders

Lihong Guan et al. Mol Neurobiol. 2022 Feb.

Abstract

Neurological disorders are primarily diseases with sophisticated etiology that are always refractory and recrudescent. The major obstruction to effective therapies for neurological disorders is the poor understanding of their pathogenic mechanisms. CRISPR-Cas9 technology, which allows precise and effective gene editing in almost any cell type and organism, is accelerating the pace of basic biological research. An increasing number of groups are focusing on uncovering the molecular mechanisms of neurological disorders and developing novel therapies using the CRISPR-Cas9 system. This review highlights the application of CRISPR-Cas9 technology in the treatment of neurological disorders, including Alzheimer's disease, amyotrophic lateral sclerosis and/or frontotemporal dementia, Duchenne muscular dystrophy, Dravet syndrome, epilepsy, Huntington's disease, and Parkinson's disease. Hopefully, it will improve our understanding of neurological disorders and give insights into future treatments for neurological disorders.

Keywords: CRISPR-Cas; Gene therapy; Genome editing; Neurological disorders.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Misra MK, Damotte V, Hollenbach JA (2018) The immunogenetics of neurological disease Immunology 153(4):399–414 - PubMed
    1. Group GBDNDC (2017) Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 16(11):877–897
    1. Feigin VL, Vos T, Nichols E, Owolabi MO, Carroll WM, Dichgans M, Deuschl G, Parmar P, Brainin M, Murray C (2020) The global burden of neurological disorders: translating evidence into policy. Lancet Neurol 19(3):255–265 - PubMed
    1. Pena SA, Iyengar R, Eshraghi RS, Bencie N, Mittal J, Aljohani A, Mittal R, Eshraghi AA (2020) Gene therapy for neurological disorders: challenges and recent advancements. J Drug Target 28(2):111–128 - PubMed
    1. Huang H, Sharma HS, Chen L, Saberi H, Mao G (2019) 2018 Yearbook of Neurorestoratology. Journal of Neurorestoratology 7(1):8–17

LinkOut - more resources